Iressa Versus Docetaxel (Taxotere)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00076388
First received: January 21, 2004
Last updated: May 12, 2011
Last verified: May 2011
  Purpose

The purpose of this study is to compare the effects of ZD1839 or docetaxel in patients with advanced non-small cell lung cancer (NSCLC) that has recurred or progressed after receiving prior treatment with platinum-based chemotherapy.


Condition Intervention Phase
Non-Small-Cell Lung Carcinoma
Drug: Gefitinib
Drug: Docetaxel
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Randomized, Open-Label, Parallel Group, International, Multicenter, Phase III Study of Oral ZD1839 (IRESSA®) Versus Intravenous Docetaxel (TAXOTERE®) in Patients With Locally Advanced or Metastatic Recurrent Non-Small Cell Lung Cancer Who Have Previously Received Platinum-Based Chemotherapy

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • To compare overall survival between ZD1839 and docetaxel

Secondary Outcome Measures:
  • To compare time to progression (TTP) between ZD1839 and docetaxel
  • To compare progression-free rates at 4 months and 6 months between ZD1839 and docetaxel
  • To compare the overall objective tumor response rate between ZD1839 and docetaxel
  • To compare patient-reported functionality (PRF) and quality of life (QoL) between ZD1839 and docetaxel
  • To compare safety and tolerability of ZD1839 and docetaxel

Estimated Enrollment: 1440
Study Start Date: February 2004
Study Completion Date: October 2007
Primary Completion Date: March 2007 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Measurable (uni dimensional) disease by RECIST criteria in a lesion not previously irradiated or non measurable disease
  • Locally advanced or metastatic NSCLC, not amenable to curative surgery or radiotherapy
  • Advanced non-small cell lung cancer (NSCLC) that has recurred or progressed after receiving prior treatment with platinum-based chemotherapy
  • WHO performance status (PS) 0-2
  • Absolute Neutrophil Count (ANC) >1.5 x 109/liter (L) and platelets >100 x 109/L
  • Life expectancy of at least 8 weeks

Exclusion Criteria:

  • Prior ZD1839 therapy
  • Prior docetaxel treatment for NSCLC
  • Less than 14 days since completion of prior radiotherapy
  • Less than 21 days since prior chemotherapy, immunotherapy or biological systemic anticancer therapy
  • Evidence of clinically active Interstitial Lung Disease
  • Other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ
  • Newly diagnosed CNS metastases that have not yet been treated with surgery and/or radiation. Patients with previously diagnosed and treated CNS metastases or spinal cord compression may be considered if they have evidence of clinically SD (no steroid therapy or steroid dose being tapered) for at least 28 days
  • Patients with pre existing peripheral neuropathy >= grade 2 (NCI CTC criteria)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00076388

  Hide Study Locations
Locations
United States, Alabama
Research Site
Birmingham, Alabama, United States
United States, California
Research Site
Fountain Valley, California, United States
Research Site
Los Angeles, California, United States, 90048
Research Site
Santa Rosa, California, United States
Research Site
Stockton, California, United States, 95204
United States, Colorado
Research Site
Colorado Springs, Colorado, United States
United States, Connecticut
Research Site
Norwich, Connecticut, United States
United States, Delaware
Research Site
Newark, Delaware, United States
United States, Florida
Research Site
Boca Raton, Florida, United States
Research Site
Orlando, Florida, United States, 32806
United States, Georgia
Research Site
Macon, Georgia, United States
Research Site
Tucker, Georgia, United States
United States, Illinois
Research Site
Skokie, Illinois, United States, 60077
United States, Kentucky
Research Site
Knoxville, Kentucky, United States
United States, Minnesota
Research Site
St. Louis Park, Minnesota, United States
United States, New York
Research Site
Great Neck, New York, United States, 11021
Research Site
Rochester, New York, United States, 14621
Research Site
Syracuse, New York, United States, 13210
United States, North Carolina
Research Site
Chapel Hill, North Carolina, United States, 27599
Research Site
Charlotte, North Carolina, United States
Research Site
Durham, North Carolina, United States, 27710
United States, Ohio
Research Site
Cleveland, Ohio, United States, 44195
United States, Oregon
Research Site
Portland, Oregon, United States
United States, Pennsylvania
Research Site
Philadelphia, Pennsylvania, United States
Research Site
Pittsburgh, Pennsylvania, United States
United States, South Carolina
Research Site
Columbia, South Carolina, United States
United States, Tennessee
Research Site
Nashville, Tennessee, United States
United States, Texas
Research Site
Austin, Texas, United States
Research Site
Dallas, Texas, United States
Research Site
Houston, Texas, United States, 77030-4009
Research Site
Tyler, Texas, United States
United States, Utah
Research Site
Salt Lake City, Utah, United States
United States, Virginia
Research Site
Fairfax, Virginia, United States
United States, Washington
Research Site
Seattle, Washington, United States
United States, Wisconsin
Research Site
Racine, Wisconsin, United States
Argentina
Research Site
Buenos Aires, Argentina
Research Site
Cordoba, Argentina
Research site
El Palomar, Argentina
Research Site
Mar del Plata, Argentina
Research Site
Quilmes, Argentina
Research Site
Rosario, Argentina
Research Site
San Miguel de Tucuman, Argentina
Research Site
Santa Fe, Argentina
Belgium
Research Site
Charleroi, Belgium
Research Site
Edegem, Belgium
Research Site
Genk, Belgium
Research Site
Godinne, Belgium
Research Site
Kortrijk, Belgium
Research Site
Leuven, Belgium
Research Site
Liège, Belgium
Research Site
Yvoir, Belgium
Brazil
Research Site
Rio de Janeiro, RJ, Brazil
Research Site
Porto Alegre, RS, Brazil
Research Site
Sao Paulo, SP, Brazil
Canada, Alberta
Research Site
Edmonton, Alberta, Canada
Canada, British Columbia
Research Site
Surrey, British Columbia, Canada
Canada, New Brunswick
Research Site
Moncton, New Brunswick, Canada
Canada, Nova Scotia
Research Site
Halifax, Nova Scotia, Canada
Canada, Ontario
Research Site
Hamilton, Ontario, Canada
Research Site
London, Ontario, Canada
Research Site
Newmarket, Ontario, Canada
Research Site
St. Catherines, Ontario, Canada
Research Site
Sudbury, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
York, Ontario, Canada
Canada, Quebec
Research Site
Laval, Quebec, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Ste-Foy, Quebec, Canada
China
Research Site
Beijing, China
Research Site
Guangzhou, China
Research Site
Shanghai, China
Croatia
Research Site
Split, Croatia
Research Site
Zagreb, Croatia
Denmark
Research Site
Aalborg, Denmark
Research Site
Arhus C, Denmark
Research Site
Glostrup, Denmark
Research Site
Herlev, Denmark
Research Site
København Ø, Denmark
Research Site
Vejle, Denmark
Estonia
Research Site
Tallinn, Estonia
Research Site
Tartu, Estonia
France
Research Site
Blois, France
Research Site
Boulogne Billancourt, France
Research Site
Caen Cedex, France
Research Site
Grenoble Cedex 09, France
Research Site
Le Mans, France
Research Site
Lille Cedex, France
Research Site
Nantes, France
Research Site
Niort, France
Research Site
Saint Herblain, France
Research Site
Vandoeuvre Les Nancy, France
Research Site
Vesoul Cedex, France
Germany
Research Site
Heidelberg, Baden-Württemberg, Germany
Research Site
Ulm, Baden-Württemberg, Germany
Research Site
Cottbus, Brandenburg, Germany
Research Site
Frankfurt, Hessen, Germany
Research Site
Düsseldorf, Nordrhein-Westfalen, Germany
Research Site
Mainz, Rheinland-Pfalz, Germany
Research Site
Bad Segeberg, Schleswig-Holstein, Germany
Research Site
Berlin, Germany
Research Site
Bonn, Germany
Research Site
Großhansdorf, Germany
Research Site
Köln, Germany
Research Site
Leverkusen, Germany
Research Site
Löwenstein, Germany
Research Site
Mannheim, Germany
Research Site
München, Germany
Research Site
Stuttgart, Germany
Research Site
Wiesbaden, Germany
Hong Kong
Research Site
Hong Kong, Hong Kong
Indonesia
Research Site
Jakarta, Indonesia
Research Site
Yogyakarta, Indonesia
Italy
Research Site
La Torretta, Ancona, Italy
Research Site
Bari, BA, Italy
Research Site
Bergamo, BG, Italy
Research Site
Bologna, BO, Italy
Research Site
Cuneo, CN, Italy
Research Site
Catania, CT, Italy
Research Site
Forli', FO, Italy
Research Site
Melegnano, MI, Italy
Research Site
Rozzano, MI, Italy
Research Site
Modena, MO, Italy
Research Site
Parma, PR, Italy
Research Site
Torino, TO, Italy
Research Site
Napoli, Italy
Research Site
Roma, Italy
Latvia
Research Site
Riga, Latvia
Malaysia
Research Site
Kuala Lumpur, Malaysia
Research Site
Nilai, Malaysia
Mexico
Research Site
Guadalajara, Mexico
Research Site
Monterrey, Mexico
Research Site
Morelia, Mexico
Research Site
Torreon, Mexico
Philippines
Research Site
Manila, Philippines
Research Site
Quezon City, Philippines
Singapore
Research Site
Singapore, Singapore
Slovenia
Research Site
Ljubliana, Slovenia
Spain
Research Site
Elche, Alicante, Spain
Research Site
Barcelona, Spain
Research Site
Gerona, Spain
Research Site
Madrid, Spain
Research Site
Málaga, Spain
Research Site
Sevilla, Spain
Research Site
Valencia, Spain
Research Site
Vitoria, Spain
Research Site
Zaragoza, Spain
Sweden
Research Site
Goteborg, Sweden
Research Site
Luleå, Sweden
Research Site
Skövde, Sweden
Research Site
Stockholm, Sweden
Research Site
Sundsvall, Sweden
Research Site
Umeå, Sweden
Research Site
Vasteras, Sweden
Research Site
Örebro, Sweden
Research Site
Östersund, Sweden
Switzerland
Research Site
Bellinzona, Switzerland
Research Site
St. Gallen, Switzerland
Research Site
Zürich, Switzerland
Thailand
Research Site
Chiang Mai, Thailand
Turkey
Research Site
Ankara, Turkey
Research Site
Istanbul, Turkey
Research Site
Izmir, Turkey
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: AstraZeneca Iressa Medical Science Director, MD AstraZeneca
  More Information

No publications provided by AstraZeneca

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00076388     History of Changes
Other Study ID Numbers: D791GC00001, EudraCT No: 2004-002943-28, 1839IL/0721
Study First Received: January 21, 2004
Last Updated: May 12, 2011
Health Authority: United States: Food and Drug Administration

Keywords provided by AstraZeneca:
Non-Small-Cell Lung Cancer

Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Bronchial Neoplasms
Carcinoma, Bronchogenic
Lung Diseases
Neoplasms
Neoplasms by Site
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
Docetaxel
Antimitotic Agents
Antineoplastic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Tubulin Modulators

ClinicalTrials.gov processed this record on October 20, 2014